The transcript for Amgen Inc.'s third quarter 2013 financial results indicates several positive and strategic developments that are likely to have a favorable short-term impact on the stock price.

- **Strong Financial Performance**: Amgen reported an 11% increase in sales and a 16% increase in earnings per share, leading to an upward revision in full-year guidance for revenues and adjusted EPS[5].
- **Strategic Expansions**: The company has made significant strides in international expansion, including a strategic alliance in Japan, a joint venture in China, and the acquisition of Onyx Pharmaceuticals. These moves are expected to drive long-term growth and were well-received by the market[5].
- **Pipeline Progress**: Amgen's R&D pipeline is robust, with multiple late-stage programs and biosimilars advancing. The upcoming data from key studies, such as those for Kyprolis and Evolocumab, are anticipated to be positive and could further boost investor confidence[5].
- **Operational Efficiency**: The end of the Enbrel profit share with Pfizer and the anticipated net benefit of around $800 million in operating income in 2014 are positive indicators of cost management and efficiency[5].

Given these positive factors, including strong financial performance, strategic expansions, and a promising pipeline, the stock is likely to see a positive impact in the short term.

[1]